Predict your next investment

Memorial Sloan Kettering Cancer Center company logo
Corporation
HEALTHCARE | Medical Facilities & Services / Hospitals
mskcc.org

See what CB Insights has to offer

Investments

6

Portfolio Exits

1

Partners & Customers

10

About Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center is committed to patient care, research, and educational programs. Its education programs train future physicians and scientists.

Memorial Sloan Kettering Cancer Center Headquarter Location

1275 York Avenue

New York, New York, 10065,

United States

212-639-2000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Memorial Sloan Kettering Cancer Center

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Memorial Sloan Kettering Cancer Center in 1 Expert Collection, including HLTH.

H

HLTH

92 items

HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare

Memorial Sloan Kettering Cancer Center Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Memorial Sloan Kettering Cancer Center Rank

Research containing Memorial Sloan Kettering Cancer Center

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Memorial Sloan Kettering Cancer Center in 1 CB Insights research brief, most recently on May 9, 2019.

Latest Memorial Sloan Kettering Cancer Center News

10:17 ET JNCCN: More People with Cancer Undergoing Radiotherapy Prefer Telemedicine to In-Person Visits

Oct 19, 2021

Researchers from Memorial Sloan Kettering Cancer Center (MSK) reviewed patient surveys before and during the COVID-19 pandemic, found higher percentage preferred telemedicine and that general patient satisfaction scores were equally high for both video conferencing and office visits. News provided by Share this article Share this article PLYMOUTH MEETING, Pa., Oct. 19, 2021 /PRNewswire/ -- New research in the October 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network  assessed patient satisfaction and preferences for telemedicine, finding 45% of people with cancer preferred telemedicine, while 34% preferred office visits, and 21% had no preference. The researchers reviewed survey responses from 1,077 radiation oncology patients across NCCN Member Institution Memorial Sloan Kettering Cancer Center (MSK)'s main campus and six regional locations across New York and New Jersey. The questionnaires were based on office and telemedicine visits between December 2019 and June 2020. In terms of patient satisfaction, most reported either no difference or improvement with telemedicine overall (91%) compared to office visits, with similar results for their confidence in their physician (90%), understanding their treatment plans (88%), and confidence their cancer will be treated appropriately (87%). "These findings provide some evidence that there is a role for telemedicine beyond the COVID-19 pandemic and that it can be a particularly useful tool for certain patients—especially those who may have challenges coming on-site for an appointment," said co-lead author Narek Shaverdian, MD, MSK Department of Radiation Oncology. "Giving patients flexibility and options by being able to see them both in-person and through telemedicine can improve access to care." Notably, the survey results found that two-thirds of respondents considered telemedicine to be a superior option when it came to treatment-related costs, such as travel and lost wages. "An individual visit to the physician's office can be costly—including transportation, parking, and time off from other activities," said co-lead author Erin F. Gillespie, MD, MSK Department of Radiation Oncology. "Telemedicine takes away most of this cost and inconvenience, and could therefore reduce the overall burden of engaging with the healthcare system. Also, the ability for family and friends to join the conversation from any location can be game-changing." The researchers found patient responses varied significantly between video conferencing versus audio. Patients who had telephone-only appointments were more likely to say they thought they would benefit more from an in-person visit. "Telemedicine can be a resource to increase access to care, but only if patients have and can use these video capabilities," said Dr. Shaverdian. "There is so much that you learn just by seeing a patient and using visual cues to guide a discussion. A voice-only encounter with a patient you've never met before is challenging." "Digital tools like telemedicine have the unfortunate potential consequence of paradoxically increasing disparities in access to care," noted Dr. Gillespie. "But the counter to that is there will be some disadvantaged patients that would not have accessed the system at all, either due to technologic barriers or travel time, and now can connect at least by phone, which is an important and positive change." "Telehealth has transformed cancer care throughout the United States, with widespread adoption in an incredibly short timeframe in response to the pandemic," commented Anne Chiang, MD, PhD, Associate Professor of Medicine, Yale Cancer Center/Smilow Cancer Hospital, a member of the NCCN Policy Advisory Group who was not involved in this research. "This is such an important study as it collects and analyzes data from more than 1,000 radiation oncology patients to compare telehealth and in-person office visits. From the viewpoint of the patient, there were no significant differences across multiple domains of patient satisfaction between types of visits. In fact, some patients preferred telehealth visits and noted that telemedicine could reduce travel costs and time. The bottom line is that this study supports the use of telehealth as a permanent transformation of the healthcare landscape." The NCCN EHR Oncology Advisory Group also recently published research in the Journal of Oncology Practice sharing the oncologist perspective on telemedicine. They surveyed 1,038 providers from 26 institutions in the summer of 2020 and found an estimated 46% of post-pandemic visits could be virtual. About JNCCN—Journal of the National Comprehensive Cancer Network More than 25,000 oncologists and other cancer care professionals across the United States read JNCCN—Journal of the National Comprehensive Cancer Network. This peer-reviewed, indexed medical journal provides the latest information about innovation in translational medicine, and scientific studies related to oncology health services research, including quality care and value, bioethics, comparative and cost effectiveness, public policy, and interventional research on supportive care and survivorship. JNCCN features updates on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), review articles elaborating on guidelines recommendations, health services research, and case reports highlighting molecular insights in patient care. JNCCN is published by Harborside. Visit  JNCCN.org . To inquire if you are eligible for a FREE subscription to JNCCN, visit  NCCN.org/jnccn/subscribe . Follow JNCCN on Twitter @JNCCN . About the National Comprehensive Cancer Network The National Comprehensive Cancer Network® ( NCCN ®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients ® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation ®. NCCN also advances continuing education , global initiatives , policy , and research collaboration and publication in oncology. Visit NCCN.org for more information and follow NCCN on Facebook @NCCNorg , Instagram @NCCNorg , and Twitter @NCCN . Media Contact:

Memorial Sloan Kettering Cancer Center Investments

6 Investments

Memorial Sloan Kettering Cancer Center has made 6 investments. Their latest investment was in Blue Note Therapeutics as part of their Series A - II on September 9, 2021.

CBI Logo

Memorial Sloan Kettering Cancer Center Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/9/2021

Series A - II

Blue Note Therapeutics

$5.2M

Yes

1

6/1/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

8/9/2019

Series D

Subscribe to see more

$99M

Subscribe to see more

10

2/21/2018

Series C

Subscribe to see more

$99M

Subscribe to see more

10

2/13/2018

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/9/2021

6/1/2021

8/9/2019

2/21/2018

2/13/2018

Round

Series A - II

Series B

Series D

Series C

Series C

Company

Blue Note Therapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$5.2M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

10

Memorial Sloan Kettering Cancer Center Portfolio Exits

1 Portfolio Exit

Memorial Sloan Kettering Cancer Center has 1 portfolio exit. Their latest portfolio exit was ORIC Pharmaceuticals on April 24, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/24/2020

IPO

$991

4

Date

4/24/2020

Exit

IPO

Companies

Valuation

$991

Acquirer

Sources

4

Memorial Sloan Kettering Cancer Center Acquisitions

2 Acquisitions

Memorial Sloan Kettering Cancer Center acquired 2 companies. Their latest acquisition was Ralph Lauren Center for Cancer Care and Prevention on August 08, 2018.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/8/2018

$991

Acquired

1

2/4/2018

Series C - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/8/2018

2/4/2018

Investment Stage

Series C - II

Companies

Subscribe to see more

Valuation

$991

Total Funding

$99M

Note

Acquired

Subscribe to see more

Sources

1

10

Memorial Sloan Kettering Cancer Center Partners & Customers

10 Partners and customers

Memorial Sloan Kettering Cancer Center has 10 strategic partners and customers. Memorial Sloan Kettering Cancer Center recently partnered with Blue Note Pharmaceuticals on September 9, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

9/15/2021

Partner

Blue Note Pharmaceuticals

United States

1

9/14/2021

Partner

Blue Note Therapeutics

United States

09:00 ET Blue Note Therapeutics Announces New Collaboration for its Prescription Digital Therapeutic Candidate

`` We are excited for this opportunity to further our partnership with Memorial Sloan Kettering Cancer Center , '' said Geoffrey Eich , CEO of Blue Note Therapeutics .

2

2/23/2021

Partner

Carrum Health

United States

7/9/2020

Licensee

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

6/22/2020

Licensee

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

9/15/2021

9/14/2021

2/23/2021

7/9/2020

6/22/2020

Type

Partner

Partner

Partner

Licensee

Licensee

Business Partner

Blue Note Pharmaceuticals

Blue Note Therapeutics

Carrum Health

Country

United States

United States

United States

Subscribe to see more

Subscribe to see more

News Snippet

09:00 ET Blue Note Therapeutics Announces New Collaboration for its Prescription Digital Therapeutic Candidate

`` We are excited for this opportunity to further our partnership with Memorial Sloan Kettering Cancer Center , '' said Geoffrey Eich , CEO of Blue Note Therapeutics .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

2

10

10

Memorial Sloan Kettering Cancer Center Team

24 Team Members

Memorial Sloan Kettering Cancer Center has 24 team members, including current Chief Financial Officer, Michael Harrington.

Name

Work History

Title

Status

Michael Harrington

Chief Financial Officer

Current

Claus Torp Jensen

Chief Technology Officer, Chief Information Officer

Current

Daniel Stein MD PhD

Chief Information Officer

Current

Brian Loomis

Chief Marketing Officer

Current

Jonathan Reichel

Peace Corps, and Howard Hughes Medical Institute

Chief Marketing Officer

Current

Name

Michael Harrington

Claus Torp Jensen

Daniel Stein MD PhD

Brian Loomis

Jonathan Reichel

Work History

Peace Corps, and Howard Hughes Medical Institute

Title

Chief Financial Officer

Chief Technology Officer, Chief Information Officer

Chief Information Officer

Chief Marketing Officer

Chief Marketing Officer

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.